, /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the final follow-up results of the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) have been published in on .
Data were presented as an oral presentation at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting on , . Further details have been posted on the corporate website . The article in was titled "Claudin18.
2-specific CAR T Cells in gastrointestinal cancers: phase 1 trial final results". The 2024 ASCO Annual Meeting abstract was titled "Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Gastrointestinal Cancers: Final Results of CT041-CG4006 Phase 1 Trial".
The leading PI of this study, Professor of Beijing Cancer Hospital, said, "Satri-cel has shown promising efficacy and manageable safety profiles in patients with Claudin18.2-positive advanced gastrointestinal cancers, particularly those with gastric cancer or gastroesophageal junction cancer. This study marks a significant advancement in the field of CAR T-cell therapy for solid tumors.
It suggests that CAR T-cell therapy has the potential to transform existing treatment paradigms and provides important reference points for further innovative .
